BN Business News
기업 추가 →
이 기사의 번역을 준비하고 있습니다. 그동안 영어 원문을 임시로 표시합니다.

규제 및 법률 · 2002. 9. 17.1 분 읽기

Prospective Grant of Co-Exclusive License: Prophylactic and/or Therapeutic Vaccine Against Pseudomonas Aeruginosa

로컬 자동 번역 · 원본 출처 언어

요약

This is notice in accordance with 15 U.S.C. 209(c)(1) and 37 CFR 404.7(a)(1)(i) that the National Institutes of Health (NIH), Department of Health and Human Services, is contemplating the grant of a limited field of use co-exclusive worldwide license to practice the inventions embodied in: U.S. Provisional Patent Application Serial Number 60/257,877, filed December 21, 2000, entitled "A Chimeric Protein Comprising Non-Toxic Pseudomonas Exotoxin A and Type IV Pilin Sequences" to Cytovax Biotechnologies Inc. of Alberta, Canada. The United States Government as represented by the Department of Health and Human Services is an assignee of these patent rights.

원본 출처 언어: Federal Register — All Documents원문 발표 열기 →